5-甲基胞嘧啶RNA甲基化在非肿瘤性肾脏疾病中的研究进展  

Current Progress of 5-Methylcytosine RNA Methylation in Non-Neoplastic Kidney Diseases

作　　者：张晨[1] 赵自霞[1] 吴私 栾军军 周华[1] ZHANG Chen;ZHAO Zixia;WU Si;LUAN Junjun;ZHOU Hua(Department of Nephrology,Shengjing Hospital of China Medical University,Shenyang 110000,China)

机构地区：[1]中国医科大学附属盛京医院肾脏内科,沈阳110000

出　　处：《中国医学科学院学报》2025年第1期86-94,共9页Acta Academiae Medicinae Sinicae

基　　金：国家自然科学基金(82170740)。

摘　　要：RNA甲基化修饰是基因表达转录后水平表观遗传学调控的关键过程。5-甲基胞嘧啶(m^(5)C)是RNA甲基化修饰的一种类型,是真核生物mRNA和其他非编码RNA中常见的转录后修饰,主要调控转运RNA稳定性,核糖体RNA组装和mRNA成熟、稳定性与翻译等生物学过程。m^(5)C RNA甲基化修饰是动态可逆的,受甲基转移酶、去甲基化酶和甲基化识别蛋白的调控。研究证实,m^(5)C RNA甲基化修饰异常与非肿瘤性肾脏疾病的发生相关。本文总结了m^(5)C RNA甲基化相关酶与非肿瘤性急慢性肾脏疾病之间的研究进展,有望为这类疾病的诊断和治疗提供潜在的靶点。RNA methylation is a key process in the epigenetic regulation of post-transcriptional gene expression.5-Methylcytosine(m^(5)C)is a type of RNA methylation,commonly existing in eukaryotic mRNA and non-coding RNAs.It mainly regulates transfer RNA stability,ribosomal RNA assembly,and mRNA translation,stability,and translation.RNA methylation is dynamically reversible and regulated by methyltransferase,demethylase,and methylation recognition protein.It has been confirmed that aberrant m^(5)C RNA methylation is involved in the pathogenesis of non-neoplastic kidney diseases.This article summarizes the current progress of m^(5)C RNA methylation associated with non-neoplastic acute and chronic kidney diseases,aiming to provide potential targets for the diagnosis and treatment of such diseases.

关 键 词：表观遗传学 RNA甲基化修饰 RNA 5-甲基胞嘧啶 肾脏疾病 

分 类 号：R692[医药卫生—泌尿科学]